Amanote Research
Register
Sign In
Prm66 - An Exploration of the Methodology for Considering Treatment Duration in Budget Impact Analyses in Oncology: A Case Study in Second Line Advanced Renal Cell Carcinoma
Value in Health
- United Kingdom
doi 10.1016/j.jval.2018.09.2187
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Date
October 1, 2018
Authors
A Medina Diaz
F Cotte
A Gaudin
P Levy
Publisher
Elsevier BV
Related search
Lenalidomide as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Exploration of Biomarkers for Treatment Efficacy
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
Nivolumab in the Treatment of Advanced Renal Cell Carcinoma
Oncology in Clinical Practice
Oncology
Economic Evaluation of Nivolumab as a Second-Line Treatment for Advanced Renal Cell Carcinoma From US and Chinese Perspectives
Cancer
Cancer Research
Oncology
Second-Line Treatment for Renal Cell Cancer
British Journal of Cancer
Cancer Research
Oncology
Pcn70 - Assessing the Budget Impact of Including Sunitinib for the Treatment of Metastatic Renal Cell Carcinoma in Argentina
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Profile of Temsirolimus in the Treatment of Advanced Renal Cell Carcinoma
OncoTargets and Therapy
Oncology
Pharmacology
Survival Benefits of Second-Line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma
Pathology and Oncology Research
Medicine
Forensic Medicine
Pathology
Oncology
Cancer Research
M-Tor Inhibitors in the Treatment of Advanced Renal Cell Carcinoma
Wspolczesna Onkologia
Oncology
Radiology
Nuclear Medicine
Imaging
Angiogenesis Genotyping in the Selection of First-Line Treatment With Either Sunitinib or Pazopanib for Advanced Renal Cell Carcinoma
Oncotarget
Oncology
